"shionogi" - Google News

Shionogi’s CVC unit takes infectious diseases specialist into new area of fertility - Global Venturing

Fri, 12 Jun 2026 10:38:16 GMT

Shionogi’s CVC unit takes infectious diseases specialist into new area of fertility Global Venturing

Shionogi (TSE:4507) Valuation Check As XOCOVA Wins First US FDA Approval For COVID 19 Post Exposure Prophylaxis - Yahoo Finance

Wed, 10 Jun 2026 20:06:59 GMT

Shionogi (TSE:4507) Valuation Check As XOCOVA Wins First US FDA Approval For COVID 19 Post Exposure Prophylaxis Yahoo Finance

Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative - Fierce Pharma

Mon, 01 Jun 2026 07:00:00 GMT

Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative Fierce Pharma

US regulator approves oral drug from Japan's Shionogi to prevent COVID-19 - Reuters

Mon, 01 Jun 2026 07:00:00 GMT

US regulator approves oral drug from Japan's Shionogi to prevent COVID-19 Reuters

Shionogi invests in Dioseve through Its CVC activities - The Pharma Letter

Fri, 12 Jun 2026 09:56:49 GMT

Shionogi invests in Dioseve through Its CVC activities The Pharma Letter

Shionogi Selected as a “DX Stock 2026”｜塩野義製薬 - Shionogi Inc.

Fri, 10 Apr 2026 07:00:00 GMT

Shionogi Selected as a “DX Stock 2026”｜塩野義製薬 Shionogi Inc.

[Press release] Shionogi announces FDA approval of XOCOVA® (ensitrelvir), the first and only oral option to help prevent COVID-19 following exposure - European AIDS Treatment Group

Thu, 04 Jun 2026 01:25:32 GMT

[Press release] Shionogi announces FDA approval of XOCOVA® (ensitrelvir), the first and only oral option to help prevent COVID-19 following exposure European AIDS Treatment Group

Shionogi Secures US Contract to Expand Antibiotic Manufacturing and Biothreat Preparedness - Contagion Live

Thu, 09 Apr 2026 07:00:00 GMT

Shionogi Secures US Contract to Expand Antibiotic Manufacturing and Biothreat Preparedness Contagion Live

Fragile X drug zatolmilast misses main goal in Phase 3 trials - Fragile X News Today

Wed, 10 Jun 2026 07:00:00 GMT

Fragile X drug zatolmilast misses main goal in Phase 3 trials Fragile X News Today

Shionogi secures BARDA contract for cefiderocol for resistant infections, bioterror threats - CIDRAP

Thu, 09 Apr 2026 07:00:00 GMT

Shionogi secures BARDA contract for cefiderocol for resistant infections, bioterror threats CIDRAP

Shionogi weighs future of FXS drug after double Phase III miss - Clinical Trials Arena

Thu, 14 May 2026 07:00:00 GMT

Shionogi weighs future of FXS drug after double Phase III miss Clinical Trials Arena

(ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure - Business Wire

Mon, 01 Jun 2026 07:00:00 GMT

(ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure Business Wire

Shionogi Receives US FDA Approval for Oral COVID-19 Post-Exposure Prophylaxis - BioSpectrum Asia

Tue, 09 Jun 2026 07:27:19 GMT

Shionogi Receives US FDA Approval for Oral COVID-19 Post-Exposure Prophylaxis BioSpectrum Asia

Tanabe Pharma America Announces Finalization of RADICAVA (edaravone) Transfer to Shionogi - PR Newswire

Wed, 01 Apr 2026 07:00:00 GMT

Tanabe Pharma America Announces Finalization of RADICAVA (edaravone) Transfer to Shionogi PR Newswire

Shionogi secures $482m BARDA contract to tackle AMR crisis - Pharmaceutical Technology

Thu, 09 Apr 2026 07:00:00 GMT

Shionogi secures $482m BARDA contract to tackle AMR crisis Pharmaceutical Technology

Shionogi Inc. Awarded $482 Million Contract with U.S. Government to Enhance National Preparedness for Drug-Resistant Bacterial Threats - Pharmaceutical Executive

Thu, 09 Apr 2026 07:00:00 GMT

Shionogi Inc. Awarded $482 Million Contract with U.S. Government to Enhance National Preparedness for Drug-Resistant Bacterial Threats Pharmaceutical Executive

Shionogi nabs initial $119M award from BARDA to establish US antibiotic plant - Fierce Pharma

Wed, 08 Apr 2026 07:00:00 GMT

Shionogi nabs initial $119M award from BARDA to establish US antibiotic plant Fierce Pharma

Shionogi Enters $2.5 Billion Agreement to Acquire All Rights to Radicava - Pharmaceutical Executive

Thu, 02 Apr 2026 07:00:00 GMT

Shionogi Enters $2.5 Billion Agreement to Acquire All Rights to Radicava Pharmaceutical Executive

ALS med Radicava to change hands as Shionogi inks $2.5B buyout - Fierce Pharma

Mon, 22 Dec 2025 08:00:00 GMT

ALS med Radicava to change hands as Shionogi inks $2.5B buyout Fierce Pharma

Shionogi lands US contract worth up to $482M to tackle superbugs, onshore production - FirstWord Pharma

Wed, 08 Apr 2026 07:00:00 GMT

Shionogi lands US contract worth up to $482M to tackle superbugs, onshore production FirstWord Pharma

Shionogi pays Apnimed $100M for joint venture to awaken sleep disorder dream - Fierce Biotech

Tue, 24 Mar 2026 07:00:00 GMT

Shionogi pays Apnimed $100M for joint venture to awaken sleep disorder dream Fierce Biotech

Is First-in-Class FDA Approval For XOCOVA PEP Altering The Investment Case For Shionogi (TSE:4507)? - simplywall.st

Mon, 08 Jun 2026 09:19:10 GMT

Is First-in-Class FDA Approval For XOCOVA PEP Altering The Investment Case For Shionogi (TSE:4507)? simplywall.st

Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone) - Business Wire

Wed, 01 Apr 2026 07:00:00 GMT

Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone) Business Wire

FDA clears Shionogi’s Xocova as first COVID-19 prevention pill - BioWorld News

Tue, 02 Jun 2026 07:00:00 GMT

FDA clears Shionogi’s Xocova as first COVID-19 prevention pill BioWorld News

Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up - Pharmaceutical Technology

Tue, 20 Jan 2026 08:00:00 GMT

Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up Pharmaceutical Technology

Pfizer to Exit ViiV Healthcare as GSK and Shionogi Reshape Ownership - Yahoo Finance

Sun, 25 Jan 2026 08:00:00 GMT

Pfizer to Exit ViiV Healthcare as GSK and Shionogi Reshape Ownership Yahoo Finance

Shionogi Acquires $2.1 Billion ViiV Healthcare Shareholdings from Pfizer - Pharmaceutical Executive

Tue, 20 Jan 2026 08:00:00 GMT

Shionogi Acquires $2.1 Billion ViiV Healthcare Shareholdings from Pfizer Pharmaceutical Executive

Pharma Pulse: Shionogi’s $2.5B Radicava Acquisition and the Industry Monitors U.S.-Iran Conflict for Supply Disruptions - Pharmaceutical Commerce

Fri, 03 Apr 2026 07:00:00 GMT

Pharma Pulse: Shionogi’s $2.5B Radicava Acquisition and the Industry Monitors U.S.-Iran Conflict for Supply Disruptions Pharmaceutical Commerce

The Power to Create Medicines That Reach Patients—Passing SHIONOGI’s Baton of Innovation to the Next Generation - Shionogi Inc.

Wed, 08 Oct 2025 07:00:00 GMT

The Power to Create Medicines That Reach Patients—Passing SHIONOGI’s Baton of Innovation to the Next Generation Shionogi Inc.

Oral Antiviral Xocova Approved for COVID-19 Post-Exposure Prophylaxis - Vaccine Advisor

Mon, 08 Jun 2026 04:00:00 GMT

Oral Antiviral Xocova Approved for COVID-19 Post-Exposure Prophylaxis Vaccine Advisor

Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company - Fierce Pharma

Tue, 20 Jan 2026 08:00:00 GMT

Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company Fierce Pharma

Shionogi’s New U.S. And China Drug Approvals Shift Growth Outlook - simplywall.st

Fri, 05 Jun 2026 10:56:43 GMT

Shionogi’s New U.S. And China Drug Approvals Shift Growth Outlook simplywall.st

Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats - Business Wire

Wed, 08 Apr 2026 07:00:00 GMT

Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats Business Wire

Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake - Reuters

Tue, 20 Jan 2026 08:00:00 GMT

Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake Reuters

Fierce Pharma Asia—China biotech deal spree rolls on; Shionogi buys Tanabe's ALS business - Fierce Pharma

Fri, 09 Jan 2026 08:00:00 GMT

Fierce Pharma Asia—China biotech deal spree rolls on; Shionogi buys Tanabe's ALS business Fierce Pharma

Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease - Business Wire

Thu, 19 Mar 2026 07:00:00 GMT

Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease Business Wire

Shionogi enrols first patients in Esprit trial for Pompe disease - Clinical Trials Arena

Fri, 20 Mar 2026 07:00:00 GMT

Shionogi enrols first patients in Esprit trial for Pompe disease Clinical Trials Arena

Shionogi ranks second in 2026 Antimicrobial Resistance Benchmark report - European Pharmaceutical Review

Tue, 19 May 2026 12:38:26 GMT

Shionogi ranks second in 2026 Antimicrobial Resistance Benchmark report European Pharmaceutical Review

Assessing Shionogi (TSE:4507) Valuation After Strong Nine‑Month Earnings And Share Price Momentum - Yahoo Finance

Wed, 04 Feb 2026 08:00:00 GMT

Assessing Shionogi (TSE:4507) Valuation After Strong Nine‑Month Earnings And Share Price Momentum Yahoo Finance

Shionogi shells out $2.5B for Mitsubishi Tanabe's ALS drug - FirstWord Pharma

Mon, 22 Dec 2025 08:00:00 GMT

Shionogi shells out $2.5B for Mitsubishi Tanabe's ALS drug FirstWord Pharma

Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Customer Shionogi & Co., Ltd. - PR Newswire

Tue, 10 Feb 2026 08:00:00 GMT

Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Customer Shionogi & Co., Ltd. PR Newswire

Shionogi’s Fetroja Contract And Data Shift U.S. Growth And Valuation Outlook - Yahoo Finance

Sun, 12 Apr 2026 07:00:00 GMT

Shionogi’s Fetroja Contract And Data Shift U.S. Growth And Valuation Outlook Yahoo Finance

Shionogi moves to acquire global rights to Radicava for ALS - ALS News Today

Thu, 08 Jan 2026 08:00:00 GMT

Shionogi moves to acquire global rights to Radicava for ALS ALS News Today

Fierce Pharma Asia—Takeda-Denali split-up; Merck, Zhifei's revised deal; Shionogi's made-in-US plan - Fierce Pharma

Fri, 10 Apr 2026 07:00:00 GMT

Fierce Pharma Asia—Takeda-Denali split-up; Merck, Zhifei's revised deal; Shionogi's made-in-US plan Fierce Pharma

Shionogi in Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® and IV RADICAVA - Cleary Gottlieb

Tue, 23 Dec 2025 08:00:00 GMT

Shionogi in Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® and IV RADICAVA Cleary Gottlieb

Shionogi Invests $2.1 Billion to Raise ViiV Healthcare Stake - Bloomberg.com

Tue, 20 Jan 2026 08:00:00 GMT

Shionogi Invests $2.1 Billion to Raise ViiV Healthcare Stake Bloomberg.com

Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science - Pharmaceutical Executive

Wed, 25 Mar 2026 07:00:00 GMT

Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science Pharmaceutical Executive

Shionogi starts phase 2 clinical trial for Pompe Disease - PMLiVE

Tue, 21 Apr 2026 07:00:00 GMT

Shionogi starts phase 2 clinical trial for Pompe Disease PMLiVE

Shionogi to Present RADICAVA® (edaravone) ORS and Digital Health Analyses in ALS at AAN 2026 - BioSpace

Fri, 17 Apr 2026 07:00:00 GMT

Shionogi to Present RADICAVA® (edaravone) ORS and Digital Health Analyses in ALS at AAN 2026 BioSpace

Pfizer exits ViiV, selling stake to Shionogi in $2.1B deal - FirstWord Pharma

Tue, 20 Jan 2026 08:00:00 GMT

Pfizer exits ViiV, selling stake to Shionogi in $2.1B deal FirstWord Pharma

Shionogi Expands Rare Disease Presence with Planned Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® (edaravone) and IV RADICAVA - Business Wire

Mon, 22 Dec 2025 08:00:00 GMT

Shionogi Expands Rare Disease Presence with Planned Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® (edaravone) and IV RADICAVA Business Wire

Shionogi to Present RADICAVA® (edaravone) ORS and Digital Health Analyses in ALS at AAN 2026 - Yahoo Finance

Thu, 16 Apr 2026 07:00:00 GMT

Shionogi to Present RADICAVA® (edaravone) ORS and Digital Health Analyses in ALS at AAN 2026 Yahoo Finance

Shionogi Increasing Stake in ViiV Healthcare for $2.1 Bn; Pfizer Exits the HIV JV - DCAT Value Chain Insights

Thu, 22 Jan 2026 08:00:00 GMT

Shionogi Increasing Stake in ViiV Healthcare for $2.1 Bn; Pfizer Exits the HIV JV DCAT Value Chain Insights

Shionogi Pill Prevents Covid in Household Exposure Study - Bloomberg.com

Wed, 13 May 2026 07:00:00 GMT

Shionogi Pill Prevents Covid in Household Exposure Study Bloomberg.com

Pfizer, GSK, Shionogi sponsor London run of musical about antimicrobial resistance - Fierce Pharma

Thu, 04 Dec 2025 08:00:00 GMT

Pfizer, GSK, Shionogi sponsor London run of musical about antimicrobial resistance Fierce Pharma

Shionogi to buy Jersey City pharma for $2.5B - NJBIZ

Tue, 23 Dec 2025 08:00:00 GMT

Shionogi to buy Jersey City pharma for $2.5B NJBIZ

FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Postexposure Prevention - Contagion Live

Tue, 02 Sep 2025 07:00:00 GMT

FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Postexposure Prevention Contagion Live

Shionogi Eyes Growth From Radicava, Torii Business This Fiscal Year - Citeline News & Insights

Wed, 13 May 2026 07:00:00 GMT

Shionogi Eyes Growth From Radicava, Torii Business This Fiscal Year Citeline News & Insights

FDA Approves Xocova as First Oral Post-Exposure Covid-19 Prevention Therapy - Pharmaceutical Executive

Mon, 01 Jun 2026 14:33:46 GMT

FDA Approves Xocova as First Oral Post-Exposure Covid-19 Prevention Therapy Pharmaceutical Executive

Shionogi (TSE:4507): Evaluating Valuation After a Strong Year-to-Date Share Price Gain - Yahoo Finance

Tue, 23 Dec 2025 08:00:00 GMT

Shionogi (TSE:4507): Evaluating Valuation After a Strong Year-to-Date Share Price Gain Yahoo Finance

Shionogi expands rare disease presence with acquisition of global rights to Tanabe's RADICAVA for $2.5 B - BioSpectrum Asia

Fri, 02 Jan 2026 08:00:00 GMT

Shionogi expands rare disease presence with acquisition of global rights to Tanabe's RADICAVA for $2.5 B BioSpectrum Asia

Yomiuri: Shionogi Inks Contract with U.S. Govt For Antibiotics Production - MarketWatch

Thu, 09 Apr 2026 07:00:00 GMT

Yomiuri: Shionogi Inks Contract with U.S. Govt For Antibiotics Production MarketWatch

Shionogi: Key Advice on Migrating to Vault CRM - Veeva

Sat, 23 Aug 2025 04:58:17 GMT

Shionogi: Key Advice on Migrating to Vault CRM Veeva

Shionogi Co: Shionogi China Has Received Approval From NMPA Of China For Naldemedine, A Treatment For Opioid-Induced Constipation - TradingView

Thu, 28 May 2026 07:00:00 GMT

Shionogi Co: Shionogi China Has Received Approval From NMPA Of China For Naldemedine, A Treatment For Opioid-Induced Constipation TradingView

SHIONOGI - The Facts

Mon, 01 Jun 2026 12:30:07 GMT

SHIONOGI The Facts

New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure - BioSpace

Thu, 14 May 2026 07:00:00 GMT

New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure BioSpace

GSK, Pfizer and Shionogi finalize changes to ViiV Healthcare ownership - Investing.com

Wed, 01 Apr 2026 07:00:00 GMT

GSK, Pfizer and Shionogi finalize changes to ViiV Healthcare ownership Investing.com

Shionogi patents new agents for HIV-1 infection - BioWorld News

Tue, 10 Mar 2026 07:00:00 GMT

Shionogi patents new agents for HIV-1 infection BioWorld News

ESCMID Global 2026: Shionogi Presents New Real-World Data Highlighting Clinical Effectiveness of Fetroja®/Fetcroja® (cefiderocol) in MBL-Producing Enterobacterales Infections - Yahoo Finance

Tue, 07 Apr 2026 07:00:00 GMT

ESCMID Global 2026: Shionogi Presents New Real-World Data Highlighting Clinical Effectiveness of Fetroja®/Fetcroja® (cefiderocol) in MBL-Producing Enterobacterales Infections Yahoo Finance

FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure - Business Wire

Tue, 02 Sep 2025 07:00:00 GMT

FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure Business Wire

Shionogi buys out Apnimed's stake in sleep-focused joint venture for $100M - FirstWord Pharma

Tue, 24 Mar 2026 07:00:00 GMT

Shionogi buys out Apnimed's stake in sleep-focused joint venture for $100M FirstWord Pharma

Shionogi Co Ltd - Shionogi's U.S. unit receives FDA approval for ensitrelvir as post-exposure prophylaxis for Covid-19 - marketscreener.com

Sun, 31 May 2026 07:00:00 GMT

Shionogi Co Ltd - Shionogi's U.S. unit receives FDA approval for ensitrelvir as post-exposure prophylaxis for Covid-19 marketscreener.com

Shionogi expands stake in ViiV Healthcare following Pfizer’s exit, GSK retains majority share - BioXconomy

Tue, 27 Jan 2026 08:00:00 GMT

Shionogi expands stake in ViiV Healthcare following Pfizer’s exit, GSK retains majority share BioXconomy

The Shionogi & Co., Ltd. (TSE:4507) Annual Results Are Out And Analysts Have Published New Forecasts - simplywall.st

Thu, 14 May 2026 07:00:00 GMT

The Shionogi & Co., Ltd. (TSE:4507) Annual Results Are Out And Analysts Have Published New Forecasts simplywall.st

Shionogi completes $2.5B deal for ALS drug Radicava rights (updated) - NJBIZ

Fri, 03 Apr 2026 07:00:00 GMT

Shionogi completes $2.5B deal for ALS drug Radicava rights (updated) NJBIZ

Shionogi makes investment in Japanese startup Restore Vision to develop visual restoration gene therapy - BioSpectrum Asia

Thu, 16 Apr 2026 07:00:00 GMT

Shionogi makes investment in Japanese startup Restore Vision to develop visual restoration gene therapy BioSpectrum Asia

Will nasal vaccines consign injections to history? - Nature

Wed, 22 Oct 2025 13:31:53 GMT

Will nasal vaccines consign injections to history? Nature

Japan’s Shionogi boosts ViiV stake in $2.13 billion deal as Pfizer exits - WTVB

Tue, 20 Jan 2026 08:00:00 GMT

Japan’s Shionogi boosts ViiV stake in $2.13 billion deal as Pfizer exits WTVB

[Press release] GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding - European AIDS Treatment Group

Tue, 20 Jan 2026 08:00:00 GMT

[Press release] GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding European AIDS Treatment Group

Global pharmaceutical company Shionogi joins Paddington Life Sciences Partners - Imperial College Healthcare NHS Trust

Mon, 10 Nov 2025 08:00:00 GMT

Global pharmaceutical company Shionogi joins Paddington Life Sciences Partners Imperial College Healthcare NHS Trust

Shionogi inks hearing loss deal with Salubritas Therapeutics - The Pharma Letter

Wed, 24 Dec 2025 08:00:00 GMT

Shionogi inks hearing loss deal with Salubritas Therapeutics The Pharma Letter

SHIONOGI - GazetteXtra

Mon, 01 Jun 2026 12:30:07 GMT

SHIONOGI GazetteXtra

Shionogi MDD drug Zurzuvae launched in Japan - The Pharma Letter

Sat, 21 Mar 2026 07:00:00 GMT

Shionogi MDD drug Zurzuvae launched in Japan The Pharma Letter

FDA Accepts Shionogi’s Ensitrelvir NDA for COVID PEP - Infectious Disease Special Edition

Fri, 05 Sep 2025 07:00:00 GMT

FDA Accepts Shionogi’s Ensitrelvir NDA for COVID PEP Infectious Disease Special Edition

Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease - Yahoo Finance

Thu, 19 Mar 2026 07:00:00 GMT

Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease Yahoo Finance

Lupin Acquires Branded Product Portfolio from Shionogi in Japan - Lupin | Press Release - lupin.com

Sat, 07 Feb 2026 20:11:08 GMT

Lupin Acquires Branded Product Portfolio from Shionogi in Japan - Lupin | Press Release lupin.com

GSK to retain majority stake in ViiV Healthcare as Pfizer exits and Shionogi increases share - Investing.com

Tue, 20 Jan 2026 08:00:00 GMT

GSK to retain majority stake in ViiV Healthcare as Pfizer exits and Shionogi increases share Investing.com

Japan's Shionogi joins World Economic Forum and signs Davos Compact on Antimicrobial Resistance - BioSpectrum Asia

Fri, 01 May 2026 07:00:00 GMT

Japan's Shionogi joins World Economic Forum and signs Davos Compact on Antimicrobial Resistance BioSpectrum Asia

Shionogi pill prevents COVID-19 in household exposure study - The Japan Times

Thu, 14 May 2026 07:00:00 GMT

Shionogi pill prevents COVID-19 in household exposure study The Japan Times

Shionogi Weighs Making Antibiotics in US Amid Rising Tariffs - Bloomberg.com

Mon, 18 Aug 2025 07:00:00 GMT

Shionogi Weighs Making Antibiotics in US Amid Rising Tariffs Bloomberg.com

GSK and Shionogi agree to replace Pfizer's stake in ViiV Healthcare - BioSpectrum Asia

Wed, 21 Jan 2026 08:00:00 GMT

GSK and Shionogi agree to replace Pfizer's stake in ViiV Healthcare BioSpectrum Asia

Shionogi Eyes US Plant to Boost Antibiotic Production Amid Tariffs Challenge - JAPAN Forward

Mon, 11 Aug 2025 07:00:00 GMT

Shionogi Eyes US Plant to Boost Antibiotic Production Amid Tariffs Challenge JAPAN Forward

Shionogi: $2.5 Billion Acquisition Of RADICAVA Establishes Rare Disease Platform - Pulse 2.0

Fri, 03 Apr 2026 07:00:00 GMT

Shionogi: $2.5 Billion Acquisition Of RADICAVA Establishes Rare Disease Platform Pulse 2.0

Fetroja Potent Against S. maltophilia Isolates - Infectious Disease Special Edition

Mon, 02 Mar 2026 08:00:00 GMT

Fetroja Potent Against S. maltophilia Isolates Infectious Disease Special Edition

Scientists uncover how vaccine adjuvants separate protection from reactogenicity - EurekAlert!

Mon, 13 Apr 2026 07:00:00 GMT

Scientists uncover how vaccine adjuvants separate protection from reactogenicity EurekAlert!

Drugmaker known for ALS medication to be acquired by Japanese company in $2.5B deal - NJ.com

Fri, 02 Jan 2026 08:00:00 GMT

Drugmaker known for ALS medication to be acquired by Japanese company in $2.5B deal NJ.com

Shionogi lifts profit outlook on HIV royalties and overseas growth - The Japan Times

Tue, 28 Oct 2025 07:00:00 GMT

Shionogi lifts profit outlook on HIV royalties and overseas growth The Japan Times

ViiV ownership shifts as Pfizer sells its stake - pharmaphorum

Tue, 20 Jan 2026 08:00:00 GMT

ViiV ownership shifts as Pfizer sells its stake pharmaphorum

BioVersys and Shionogi agree to develop ansamycin leads - Pharmaceutical Technology

Thu, 03 Jul 2025 07:00:00 GMT

BioVersys and Shionogi agree to develop ansamycin leads Pharmaceutical Technology

Preparedness requires building countermeasures before crisis - The Pharma Letter

Wed, 14 Jan 2026 08:00:00 GMT

Preparedness requires building countermeasures before crisis The Pharma Letter

"shionogi" - Google News

Shionogi’s CVC unit takes infectious diseases specialist into new area of fertility - Global Venturing

Shionogi (TSE:4507) Valuation Check As XOCOVA Wins First US FDA Approval For COVID 19 Post Exposure Prophylaxis - Yahoo Finance

Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative - Fierce Pharma

US regulator approves oral drug from Japan's Shionogi to prevent COVID-19 - Reuters

Shionogi invests in Dioseve through Its CVC activities - The Pharma Letter

Shionogi Selected as a “DX Stock 2026”｜ 塩野義製薬 - Shionogi Inc.

[Press release] Shionogi announces FDA approval of XOCOVA® (ensitrelvir), the first and only oral option to help prevent COVID-19 following exposure - European AIDS Treatment Group

Shionogi Secures US Contract to Expand Antibiotic Manufacturing and Biothreat Preparedness - Contagion Live

Fragile X drug zatolmilast misses main goal in Phase 3 trials - Fragile X News Today

Shionogi secures BARDA contract for cefiderocol for resistant infections, bioterror threats - CIDRAP

Shionogi weighs future of FXS drug after double Phase III miss - Clinical Trials Arena

(ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure - Business Wire

Shionogi Receives US FDA Approval for Oral COVID-19 Post-Exposure Prophylaxis - BioSpectrum Asia

Tanabe Pharma America Announces Finalization of RADICAVA (edaravone) Transfer to Shionogi - PR Newswire

Shionogi secures $482m BARDA contract to tackle AMR crisis - Pharmaceutical Technology

Shionogi Inc. Awarded $482 Million Contract with U.S. Government to Enhance National Preparedness for Drug-Resistant Bacterial Threats - Pharmaceutical Executive

Shionogi nabs initial $119M award from BARDA to establish US antibiotic plant - Fierce Pharma

Shionogi Enters $2.5 Billion Agreement to Acquire All Rights to Radicava - Pharmaceutical Executive

ALS med Radicava to change hands as Shionogi inks $2.5B buyout - Fierce Pharma

Shionogi lands US contract worth up to $482M to tackle superbugs, onshore production - FirstWord Pharma

Shionogi pays Apnimed $100M for joint venture to awaken sleep disorder dream - Fierce Biotech

Is First-in-Class FDA Approval For XOCOVA PEP Altering The Investment Case For Shionogi (TSE:4507)? - simplywall.st

Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone) - Business Wire

FDA clears Shionogi’s Xocova as first COVID-19 prevention pill - BioWorld News

Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up - Pharmaceutical Technology

Pfizer to Exit ViiV Healthcare as GSK and Shionogi Reshape Ownership - Yahoo Finance

Shionogi Acquires $2.1 Billion ViiV Healthcare Shareholdings from Pfizer - Pharmaceutical Executive

Pharma Pulse: Shionogi’s $2.5B Radicava Acquisition and the Industry Monitors U.S.-Iran Conflict for Supply Disruptions - Pharmaceutical Commerce

The Power to Create Medicines That Reach Patients—Passing SHIONOGI’s Baton of Innovation to the Next Generation - Shionogi Inc.

Oral Antiviral Xocova Approved for COVID-19 Post-Exposure Prophylaxis - Vaccine Advisor

Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company - Fierce Pharma

Shionogi’s New U.S. And China Drug Approvals Shift Growth Outlook - simplywall.st

Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats - Business Wire

Pfizer to exit ViiV Healthcare in $1.9 billion deal as Shionogi doubles stake - Reuters

Fierce Pharma Asia—China biotech deal spree rolls on; Shionogi buys Tanabe's ALS business - Fierce Pharma

Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease - Business Wire

Shionogi enrols first patients in Esprit trial for Pompe disease - Clinical Trials Arena

Shionogi ranks second in 2026 Antimicrobial Resistance Benchmark report - European Pharmaceutical Review

Assessing Shionogi (TSE:4507) Valuation After Strong Nine‑Month Earnings And Share Price Momentum - Yahoo Finance

Shionogi shells out $2.5B for Mitsubishi Tanabe's ALS drug - FirstWord Pharma

Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Customer Shionogi & Co., Ltd. - PR Newswire

Shionogi’s Fetroja Contract And Data Shift U.S. Growth And Valuation Outlook - Yahoo Finance

Shionogi moves to acquire global rights to Radicava for ALS - ALS News Today

Fierce Pharma Asia—Takeda-Denali split-up; Merck, Zhifei's revised deal; Shionogi's made-in-US plan - Fierce Pharma

Shionogi in Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® and IV RADICAVA - Cleary Gottlieb

Shionogi Invests $2.1 Billion to Raise ViiV Healthcare Stake - Bloomberg.com

Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science - Pharmaceutical Executive

Shionogi starts phase 2 clinical trial for Pompe Disease - PMLiVE

Shionogi to Present RADICAVA® (edaravone) ORS and Digital Health Analyses in ALS at AAN 2026 - BioSpace

Pfizer exits ViiV, selling stake to Shionogi in $2.1B deal - FirstWord Pharma

Shionogi Expands Rare Disease Presence with Planned Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® (edaravone) and IV RADICAVA - Business Wire

Shionogi to Present RADICAVA® (edaravone) ORS and Digital Health Analyses in ALS at AAN 2026 - Yahoo Finance

Shionogi Increasing Stake in ViiV Healthcare for $2.1 Bn; Pfizer Exits the HIV JV - DCAT Value Chain Insights

Shionogi Pill Prevents Covid in Household Exposure Study - Bloomberg.com

Pfizer, GSK, Shionogi sponsor London run of musical about antimicrobial resistance - Fierce Pharma

Shionogi to buy Jersey City pharma for $2.5B - NJBIZ

FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Postexposure Prevention - Contagion Live

Shionogi Eyes Growth From Radicava, Torii Business This Fiscal Year - Citeline News & Insights

FDA Approves Xocova as First Oral Post-Exposure Covid-19 Prevention Therapy - Pharmaceutical Executive

Shionogi (TSE:4507): Evaluating Valuation After a Strong Year-to-Date Share Price Gain - Yahoo Finance

Shionogi expands rare disease presence with acquisition of global rights to Tanabe's RADICAVA for $2.5 B - BioSpectrum Asia

Yomiuri: Shionogi Inks Contract with U.S. Govt For Antibiotics Production - MarketWatch

Shionogi: Key Advice on Migrating to Vault CRM - Veeva

Shionogi Co: Shionogi China Has Received Approval From NMPA Of China For Naldemedine, A Treatment For Opioid-Induced Constipation - TradingView

SHIONOGI - The Facts

New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure - BioSpace

GSK, Pfizer and Shionogi finalize changes to ViiV Healthcare ownership - Investing.com

Shionogi patents new agents for HIV-1 infection - BioWorld News

ESCMID Global 2026: Shionogi Presents New Real-World Data Highlighting Clinical Effectiveness of Fetroja®/Fetcroja® (cefiderocol) in MBL-Producing Enterobacterales Infections - Yahoo Finance

FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure - Business Wire

Shionogi buys out Apnimed's stake in sleep-focused joint venture for $100M - FirstWord Pharma

Shionogi Co Ltd - Shionogi's U.S. unit receives FDA approval for ensitrelvir as post-exposure prophylaxis for Covid-19 - marketscreener.com

Shionogi expands stake in ViiV Healthcare following Pfizer’s exit, GSK retains majority share - BioXconomy

The Shionogi & Co., Ltd. (TSE:4507) Annual Results Are Out And Analysts Have Published New Forecasts - simplywall.st

Shionogi completes $2.5B deal for ALS drug Radicava rights (updated) - NJBIZ

Shionogi makes investment in Japanese startup Restore Vision to develop visual restoration gene therapy - BioSpectrum Asia

Will nasal vaccines consign injections to history? - Nature

Japan’s Shionogi boosts ViiV stake in $2.13 billion deal as Pfizer exits - WTVB

[Press release] GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding - European AIDS Treatment Group

Shionogi Selected as a “DX Stock 2026”｜塩野義製薬 - Shionogi Inc.